Vyalev combines foscarbidopa, a prodrug of carbidopa, and foslevodopa, a prodrug of levodopa, into a solution for continuous subcutaneous 24-hour infusion. The Food and Drug Administration (FDA) has ...
VYALEV™ is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease Adults treated with VYALEV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results